AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 16946455
Drug: Structured treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Structured treatment interruption (STI) of antiretroviral therapy
Trial: 12723462
Drug: Trazodone with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trazodone with low-dose ritonavir (200 mg each, four doses)
Trial: 12723462
Drug: Trazodone with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trazodone with low-dose ritonavir
Trial: 30371800
Drug: Chemotherapy +
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy + goserelin
Trial: 26690356
Drug: Letrozole (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Letrozole (0.1 mg/kg)
Trial: 26690356
Drug: Cabergoline (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabergoline (100 µg/kg)
Trial: 17351370
Drug: Losartan 50
RxNorm normalized name: LOSARTAN 50MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan 50 mg twice daily for 4 weeks
Trial: 17351370
Drug: Atenolol 50
RxNorm normalized name: atenolol 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol 50 mg twice daily for 4 weeks
Trial: 16318148
Drug: Acupuncture and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture and moxibustion plus Chinese medicine
Trial: 16318148
Drug: Simple Chinese
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simple Chinese medicine
Trial: 9773700
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg oxycodone and 10 mL 0.5% bupivacaine (group OB)
Trial: 9773700
Drug: 10 mL
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mL 0.5% bupivacaine (group B)
Trial: 2496213
Drug: Low-dose calcium
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose calcium and phosphorus (5 mM each; 20 mg/dl of Ca and 15.5 mg/dl of P)
Trial: 2496213
Drug: High-dose calcium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose calcium and phosphorus (15 mM each; 60 mg/dl of Ca and 46.5 mg/dl of P)
Trial: 2496213
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (low and high-dose)
Trial: 21666556
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg dexamethasone administered in 100 mL of physiologic saline given intravenously 20 minutes before anesthesia induction
Trial: 21666556
Drug: 2 mL
RxNorm normalized name: ethanol 2 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mL NaCl 0.9% in 100 mL of physiologic saline (control group)
Trial: 19417877
Drug: Ketoprofen (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoprofen (50 mg)
Trial: 14968598
Drug: PCEA with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCEA with background infusion (3 ml PCEA, lock out 30 min, continuous infusion 5 ml/hr)
Trial: 14968598
Drug: Infuser group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infuser group (continuous infusion 5 ml/hr)
Trial: 14968598
Drug: PCEA with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCEA with background infusion
Trial: 9160657
Drug: Interferon alpha2b
RxNorm normalized name: Fibroblast interferon
DrugBank: Human interferon beta (DB14999)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon alpha2b 3 million U three times weekly for 12 months
Trial: 7695058
Drug: terfenadine 120
RxNorm normalized name: terfenadine 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: terfenadine 120 mg once a day
Trial: 3302705
Drug: Cop 1
RxNorm normalized name: COP 1
DrugBank: Glatiramer (DB05259)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cop 1 (20 mg daily for two years)
Trial: 3302705
Drug: Placebo (saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (saline alone daily for two years)
Trial: 3302705
Drug: Cop 1
RxNorm normalized name: COP 1
DrugBank: Glatiramer (DB05259)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cop 1 (20 mg daily for two years) among less disabled patients (Kurtzke score 0 to 2)
Trial: 3302705
Drug: Cop 1
RxNorm normalized name: COP 1
DrugBank: Glatiramer (DB05259)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cop 1 (20 mg daily for two years) among more disabled patients (Kurtzke score 3 to 6)
Trial: 3302705
Drug: Cop 1
RxNorm normalized name: COP 1
DrugBank: Glatiramer (DB05259)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cop 1 (20 mg daily for two years) among less disabled patients
Trial: 3302705
Drug: Cop 1
RxNorm normalized name: COP 1
DrugBank: Glatiramer (DB05259)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cop 1 (20 mg daily for two years) among more disabled patients
Trial: 22802308
Drug: Anastrozole (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anastrozole (1 mg per day) for 3 months
Trial: 22802308
Drug: Letrozole (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Letrozole (2.5 mg per day) for 3 months
Trial: 19874198
Drug: Odanacatib (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Odanacatib (all doses)
Trial: 18310545
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose methylprednisolone and rituximab
Trial: 18310545
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose methylprednisolone alone
Trial: 12209697
Drug: High-dose interferon
RxNorm normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose interferon alpha2b (HDI)
Trial: 12209697
Drug: Low-dose interferon
RxNorm normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose interferon alpha2b (LDI)
Trial: 12209697
Drug: High-dose interferon
RxNorm normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose interferon alpha2b (HDI) and Low-dose interferon alpha2b (LDI)
Trial: 10522576
Drug: Femoral nerve
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Femoral nerve block (15 mL bupivacaine 0.5%) and 1 mL normal saline i.v. (FNB group)
Trial: 10522576
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg (1 mL) ketorolac i.v. (KT group)
Trial: 10522576
Drug: Placebo femoral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo femoral nerve block (15 mL normal saline) and 1 mL normal saline i.v. (PL group)
Trial: 1970552
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg of an i.v. immunoglobulin preparation (ivIg)/kg body weight every other week
Trial: 30969452
Drug: Taking joint
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taking joint pain medication
Trial: 27329923
Drug: Sublingual immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual immunotherapy with House Dust Mite allergen extract
Trial: 21992121
Drug: BIBF 1120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIBF 1120 150 mg twice a day
Trial: 10767815
Drug: Early vigorous
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early vigorous medical exercise therapy (8-week active rehabilitation program with vigorous lumbar stabilizing exercises)
Trial: 9370387
Drug: Clonidine 0.2
RxNorm normalized name: CLONIDINE 0.2MG/24HR PATCH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine 0.2 mg twice daily
Trial: 9370387
Drug: Diltiazem CD
RxNorm normalized name: Diltiazem Hydrochloride 300 MG Oral Capsule, Extended Release, 24 HR [DILTIAZEM CD]
DrugBank: Diltiazem (DB00343)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Diltiazem CD 300 mg daily
Trial: 3943266
Drug: Lanoxin (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lanoxin (0.5 mg)
Trial: 3943266
Drug: Lanoxicaps (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lanoxicaps (0.4 mg)
Trial: 30923022
Drug: 2-week supply
RxNorm normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 2-week supply of nicotine patches and/or lozenges (NRT)
Trial: 29277895
Drug: Enzalutamide (ENZ)
RxNorm normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Enzalutamide (ENZ) and CCX771 (CXCR7 inhibitor) combination treatment
Trial: 29277895
Drug: CCX771 (CXCR7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CCX771 (CXCR7 inhibitor)
Trial: 22447495
Drug: CT-D (Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CT-D (Cognitive Therapy targeting overestimations of danger)
Trial: 22447495
Drug: CT-R (Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CT-R (Cognitive Therapy targeting inflated beliefs of personal responsibility)
Trial: 11787924
Drug: Transdermal 17‐beta
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal 17‐beta oestradiol 50 microg/day for 21 days (cyclical therapy)
Trial: 11787924
Drug: Continuous transdermal
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous transdermal 17‐beta oestradiol 50 microg/day
Trial: 9480174
Drug: Insulin dependent
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin dependent diabetes mellitus (IDDM)
Trial: 9480174
Drug: Non insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Non insulin dependent diabetes mellitus (NIDDM)
Trial: 31431080
Drug: Intravenous oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous oxytocin infusion (0.32 U/min) 20 min before ultrasound-guided percutaneous microwave ablation
Trial: 29506157
Drug: Isoglycemic intravenous
RxNorm normalized name: ioglycamic acid
DrugBank: Ioglycamic acid (DB13741)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoglycemic intravenous glucose infusion (IIGI)
Trial: 27533305
Drug: IIGI with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IIGI with glucagon infusion (0.8 ng/kg/min from 0 to 25 minutes)
Trial: 24857100
Drug: Weekly carboplatin/paclitaxel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly carboplatin/paclitaxel X 5 and 41.4 Gy concurrent radiotherapy followed by surgery
Trial: 20975104
Drug: High-molecular-weight (HMW)
RxNorm normalized name: High molecular weight insulin human
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-molecular-weight (HMW) carbohydrate solution
Trial: 20975104
Drug: Low-molecular-weight (LMW)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-molecular-weight (LMW) carbohydrate solution
Trial: 20975104
Drug: Comparison between
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison between HMW and LMW solutions
Trial: 17953788
Drug: Citrulline (CIT)
DrugBank: Citrulline (DB00155)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Citrulline (CIT) (all doses)
Trial: 16514811
Drug: Allicor (a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allicor (a long‐acting garlic drug) for 12 months
Trial: 7577484
Drug: Clodronate 1500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clodronate 1500 mg
Trial: 14690159
Drug: Clodronate 900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clodronate 900 mg
Trial: 9059473
Drug: Regular inhaled
RxNorm normalized name: insulin, regular, human Inhalation Powder [Afrezza]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular inhaled salbutamol for four weeks
Trial: 3571097
Drug: Liquid carbohydrate
RxNorm normalized name: pyrrolidone carboxylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid carbohydrate (LCHO) 45 g
Trial: 3571097
Drug: Solid carbohydrate
RxNorm normalized name: Corydalis solida whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solid carbohydrate confectionery bar (SCHO) 45 g
Trial: 3571097
Drug: High-CHO meal
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-CHO meal (200 g) + Solid carbohydrate confectionery bar (M + SCHO)
Trial: 30453477
Drug: Daily tryptophan
RxNorm normalized name: Tryptophan
DrugBank: Tryptophan (DB00150)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daily tryptophan intake
Trial: 30453477
Drug: Daily protein
RxNorm normalized name: Supra Clens Daily Protein Remover
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily protein intake
Trial: 30453477
Drug: Daily energy
RxNorm normalized name: CVS Daily Energy Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily energy intake
Trial: 30453477
Drug: Serum insulin-like
RxNorm normalized name: insulin-like growth factor 2
DrugBank: Insulin-like growth factor II (DB14472)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum insulin-like growth factor-1 (IGF-1)
Trial: 20653695
Drug: nebicapone 150
RxNorm normalized name: Nebicapone
DrugBank: Nebicapone (DB14849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nebicapone 150 mg
Trial: 20653695
Drug: entacapone 200
RxNorm normalized name: entacapone 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: entacapone 200 mg (active control)
Trial: 20653695
Drug: nebicapone 50
RxNorm normalized name: Nebicapone
DrugBank: Nebicapone (DB14849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nebicapone 50 mg
Trial: 20653695
Drug: nebicapone 100
RxNorm normalized name: Nebicapone
DrugBank: Nebicapone (DB14849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nebicapone 100 mg
Trial: 11151264
Drug: Topical nonpreserved
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical nonpreserved steroids for 2 weeks followed by punctal occlusion
Trial: 8656364
Drug: Pressure patching
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pressure patching after application of antibiotic/steroid ointment (A/S)
Trial: 8656364
Drug: A/S ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A/S ointment twice a day without patching
Trial: 1290331
Drug: Lo-Estrin (norethindrone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lo-Estrin (norethindrone acetate 1.5 mg plus ethinyl estradiol 0.030 mg)
Trial: 1290331
Drug: Lo-Femenal (norgestrel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lo-Femenal (norgestrel 0.30 mg plus ethinyl estradiol 0.030 mg)
Trial: 6721124
Drug: Flunitrazepam (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flunitrazepam (1 mg orally the night before operation and 1 mg on the morning of operation)
Trial: 6721124
Drug: Pentobarbital (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentobarbital (100 mg orally the night before operation) + Atropine (0.01 mg/kg intramuscular) + Pethidine (1 mg/kg intramuscular on the morning of operation)
Trial: 16675212
Drug: Salmeterol/fluticasone propionate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmeterol/fluticasone propionate combination (SFC) 50/250 microg one inhalation twice daily (bid)
Trial: 16675212
Drug: Formoterol/budesonide combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formoterol/budesonide combination (FBC) 6/200 microg two inhalations bid
Trial: 15449510
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg hyaluronate/2.5 ml (verum)
Trial: 15449510
Drug: 0.25 mg
RxNorm normalized name: biotin 0.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 mg hyaluronate/2.5 ml (control)
Trial: 22995543
Drug: Group PF
RxNorm normalized name: PF-06459988
DrugBank: PF-06459988 (DB14768)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group PF (2 mg/kg propofol+1 mcg/kg fentanyl)
Trial: 22995543
Drug: Group P
RxNorm normalized name: High mobility group protein HMGI-C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group P (2 mg/kg propofol alone)
Trial: 22995543
Drug: Group PMF
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group PMF (2 mg/kg propofol+1 mcg/kg fentanyl+0.02 mg/kg midazolam)
Trial: 22995543
Drug: Group E
RxNorm normalized name: Prostaglandin group E
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group E (0.2 mg/kg etomidate alone)
Trial: 22995543
Drug: Group EF
RxNorm normalized name: Klor-Con/EF
DrugBank: Potassium bicarbonate (DB11098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group EF (0.2 mg/kg etomidate+1 mcg/kg fentanyl)
Trial: 22995543
Drug: Group EMF
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group EMF (0.2 mg/kg etomidate+1 mcg/kg fentanyl+0.02 mg/kg midazolam)
Trial: 22321279
Drug: tolvaptan 15
RxNorm normalized name: tolvaptan 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tolvaptan 15 - 60 mg daily
Trial: 19950759
Drug: Bio-calcium from
RxNorm normalized name: Bio-Kool
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bio-calcium from shells Pinctada maxima (260 mg of elemental calcium, three times a day)
Trial: 19950759
Drug: Inorganic CaCO3
RxNorm normalized name: Organic germanium
DrugBank: Propagermanium (DB17608)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inorganic CaCO3 (500 mg daily)
Trial: 15353386
Drug: Recruitment strategy
RxNorm normalized name: Humanized Bi-Specific Xmab(R) T Cell Recruiting Antibody Construct Directed Against Cd3 And Cd38
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recruitment strategy from professional sources (e.g., community agencies)
Trial: 15353386
Drug: Recruitment strategy
RxNorm normalized name: Humanized Bi-Specific Xmab(R) T Cell Recruiting Antibody Construct Directed Against Cd3 And Cd38
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recruitment strategy from non-professional sources (e.g., health fairs)
Trial: 12136614
Drug: Antiarrhythmic agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiarrhythmic agents (mainly amiodarone)
Trial: 9534006
Drug: Oscillations of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oscillations of cytoplasmic Ca2+ concentration [(Ca2+]i) in beta cells; specific dosage and duration not available.
Trial: 9534006
Drug: Insulin secretion;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin secretion; specific dosage and duration not available.
Trial: 7698624
Drug: Omeprazole (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole (40 mg daily) and Amoxicillin (1 g twice daily) for 2 weeks (Group A)
Trial: 7698624
Drug: Omeprazole (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole (40 mg daily) alone for 2 weeks (Group B)
Trial: 30558758
Drug: Optimized medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimized medical therapy (OMT)
Trial: 25880052
Drug: Pentoxifylline 400
RxNorm normalized name: pentoxifylline 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentoxifylline 400 mg three times a day for 3 days before operation
Trial: 23996340
Drug: Lansoprazole (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole (30 mg/day) for 4 weeks
Trial: 23996340
Drug: Lansoprazole (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole (30 mg/day) for 8 weeks
Trial: 17445902
Drug: Bromfenac ophthalmic
RxNorm normalized name: bromfenac ophthalmic
DrugBank: Bromfenac (DB00963)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bromfenac ophthalmic solution 0.09% (Xibrom)
Trial: 11254817
Drug: Inhaled corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled corticosteroids (budesonide, beclomethasone dipropionate)
Trial: 11254817
Drug: Non-corticosteroid treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-corticosteroid treatment (reference group)
Trial: 9881085
Drug: D10 Group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D10 Group (10 mg dexamethasone)
Trial: 9881085
Drug: D20 Group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D20 Group (20 mg dexamethasone)
Trial: 9881085
Drug: D2 Group
RxNorm normalized name: vitamin D2
DrugBank: Ergocalciferol (DB00153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: D2 Group (not specified dexamethasone dosage)
Trial: 28960244
Drug: Case-only approach
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Case-only approach for measuring markers predicting treatment effects
Trial: 29441973
Drug: Compound clotrimazole
RxNorm normalized name: Clotrimazole
DrugBank: Clotrimazole (DB00257)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Compound clotrimazole cream (control)
Trial: 19520901
Drug: Shame transformation
RxNorm normalized name: transforming growth factor beta 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shame transformation treatment program
Trial: 11115460
Drug: Isotonic glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotonic glucose infusion
Trial: 8784112
Drug: Tirilazad mesylate,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tirilazad mesylate, 6 mg/kg per day for 3 days
Trial: 1628130
Drug: Pentaglobin (IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentaglobin (IgM and IgA enriched intravenous immunoglobulin)
Trial: 6381968
Drug: Oestrogen/progestogen +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oestrogen/progestogen + Calcium (0.5 g daily)
Trial: 6381968
Drug: Placebo +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo + Calcium (0.5 g daily)